Últimas noticias sobre Progyny (NASDAQ:PGNY) Bolsa

Progyny

Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

IBRX

PGNY

Explora las acciones de salud más sobrevendidas según el RSI. Descubre cuáles podrían ser grandes oportunidades de inversión en el mercado.

3 acciones de salud infravaloradas: Oportunidades para inversores astutos

Progyny Inc

Hartshead Resources NL

Citigroup analyst Alicia Yap upgrades PDD Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) from Neutral to Buy and raises the price target from $127 to $165.

Upgrades

Price Target

Analyst Ratings

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Citigroup Upgrades PDD Holdings to Buy, Raises Price Target to $165

Canaccord Genuity analyst Joseph Vafi maintained a Buy rating on Hut 8 Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) and <a href="https://www.benzinga.com/quote/HUT/analyst-ratings" target="_blank" rel="noreferrer noopener">reiterated the $32 price forecast</a>.
The analyst writes that he sees consistent progress at Hut 8 under the leadership of CEO Asher Genoot and his team, who have been in place for approximately five quarters.
While the past year has primarily involved operational streamlining and realignment within Hut 8, Vafi believes the future holds more significant potential.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45324398/hut-8-analysts-still-bullish-despite-q1-miss-bets-on-american-bitcoin-hpc-ai-potential" rel="noreferrer noopener">Hut 8 Analysts Still Bullish Despite Q1 Miss; Bets On American Bitcoin, HPC/AI Potential</a>
Specifically, the analyst expects Hut 8 to navigate the complex challenge of maximizing the value of its Bitcoin (CRYPTO: BTC/USD) miner power portfolio and existing assets while simultaneously pursuing emerging opportunities in AI hosting without hindering either endeavor.
The analyst notes that the U.S. Bitcoin miners have grown via capital markets, but public markets often undervalue them despite strong returns and potential cost advantage over direct BTC buys.
The analyst adds that the company&#8217;s American Bitcoin vision might prioritize BTC accumulation over max mining output, potentially mirroring MicroStrategy&#8217;s treasury success.
Overall, the involvement of Eric and Donald Trump Jr. in American Bitcoin suggests that the new company&#8217;s activities will likely extend beyond solely mining Bitcoin, writes the analyst.
Today, Gryphon Digital Mining, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) disclosed a definitive stock-for-stock merger deal with American Bitcoin, a majority-owned subsidiary of&nbsp;Hut 8, <a target="_blank" href="https://www.benzinga.com//node/45347101" rel="noreferrer noopener">for an undisclosed amount</a>. Upon closing, the combined entity will operate under the American Bitcoin brand and is expected to trade on the Nasdaq under the ticker &#8220;ABTC.&#8221;
On Thursday, Hut 8 reported a loss per share of&nbsp;$1.30, below the estimated&nbsp;24 cents, and sales of&nbsp;$21.82 million&nbsp;fell short&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45279838/hut-8-reports-first-quarter-2025-results" rel="noreferrer noopener">of the estimated&nbsp;$33.28 million</a>.
Price Action: HUT shares are up 11.1% at $15.43&nbsp;at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45017261/bitcoin-mining-costs-jump-to-137000-per-coin-when-accounting-for-non-cash-expenses-coinshares" target="_blank" rel="noreferrer noopener">Bitcoin Mining Costs Jump To $137,000 Per Coin When Accounting For Non-Cash Expenses: CoinShares</a></li>
</ul>
Image via Shutterstock

Analyst Color

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Large Cap

Reiteration

Movers

GRYP

American Bitcoin Spin-Off, AI Ambitions To Boost Hut 8 Stock: Analyst

WIIM

Prologis shares are trading higher after Scotiabank raised its price target on the stock from $97 to $100.

<a href="https://www.bloomberg.com/news/articles/2025-05-12/apple-plans-ai-powered-battery-management-mode-for-devices-in-ios-19?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-12/apple-plans-ai-powered-battery-management-mode-for-devices-in-ios-19?embedded-checkout=true</a>

General

AAPL

'Apple Plans AI-Powered Battery Management Mode for Devices in iOS 19'- Bloomberg

Ladenburg Thalmann analyst Mickey Schleien upgrades SLR Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRC#NASDAQ">SLRC</a>) from Neutral to Buy and announces $16.5 price target.

SLRC

Ladenburg Thalmann Upgrades SLR Inv to Buy, Announces $16.5 Price Target

Analysts are expressing views on Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) prior to its <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">earnings release on May 15</a>.
On Monday, Telsey Advisory Analyst Joseph Feldman maintained the Outperform <a href="https://www.benzinga.com/quote/WMT/analyst-ratings" target="_blank" rel="noreferrer noopener">rating and price forecast of $115.</a>
The analyst maintained the first quarter (Q1) estimates of 3.8% sales growth to $167.6 billion vs. FactSet consensus (FS) of $165.7 billion and adjusted EPS of $0.56 (FS: $0.57).
Feldman expects the quarter to benefit from grocery share gains, improving non-discretionary, e-commerce/marketplace progress, rollbacks, and broader wallet share (including higher-income).
Also Read: <a href="https://www.benzinga.com/markets/25/05/45342977/trumps-tariffs-reportedly-push-walmart-and-target-toy-suppliers-to-the-brink-of-closure-if-nothing-changes-well-be-crippled" target="_blank" rel="noreferrer noopener">Trump&#8217;s Tariffs Reportedly Push Walmart And Target Toy Suppliers To The Brink Of Closure: &#8216;If Nothing Changes, We&#8217;ll Be Crippled&#8217;</a>
The analyst adds that similar to recent trends at Amazon and Costco, Q1 sales could see a pull-forward in select categories like electronics.
Feldman writes that these positive factors are expected to be partially offset by selective consumer spending (especially on discretionary items) and unfavorable FX trends.
Overall, Feldman expects Walmart to navigate the current uncertain environment effectively.
For 2025, the analyst estimates sales growth of 4.0% to $708 billion, vs. the FS of 3.6% ($705 billion) and consistent with Walmart&#8217;s reiterated <a target="_blank" href="https://www.benzinga.com/news/guidance/25/04/44711688/walmart-maintains-steady-growth-forecast-despite-tariffs" rel="noreferrer noopener">April guidance of 3%-4% (constant currency)</a>.
The analyst sees adjusted EPS of $2.56 vs. FS of $2.60 and within <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">Walmart&#8217;s $2.50-$2.60 guidance range</a>.
The analyst anticipate continued selective consumer spending amid tariff-driven uncertainty regarding inventory and prices.
Meanwhile, additional tariffs, such as the current elevated rates on China, could necessitate significant actions, including potential price increases, to protect profits, adds the analyst.
B Of A Securities analyst Robert F. Ohmes kept the Buy rating with a price forecast of $120.
The analyst estimates adjusted EPS of $0.59 and a 3% increase in U.S. comparable sales for Q1, with comparable sales forecast indicating a deceleration compared to the fourth quarter.
Ohmes says that the estimates incorporate impacts from lapping the leap day last year (-100 basis point headwind to sales and -250 basis points to EBIT), the Vizio acquisition (a +15 basis point benefit to sales but a -70 basis point impact on EBIT), and foreign exchange.
The analyst writes that while not entirely shielded, Walmart is well-equipped to handle tariffs due to its strong supplier relationships, sophisticated pricing and automation strategies, effective inventory management, and the option to transition some directly sold (1P) imported goods to its third-party (3P) marketplace.
The analyst adds that given that groceries have a lower import exposure (they constitute 60% of Walmart&#8217;s U.S. sales), the company&#8217;s overall import exposure is limited to roughly one-third of its total U.S. business.
Price Action: WMT shares are down 0.4% at $96.26 at the last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/05/45213125/bill-ackman-says-inflation-has-largely-been-wrung-out-pushes-for-temporary-pause-on-china-tariffs-to-shield-us-businesses" target="_blank" rel="noreferrer noopener">Bill Ackman Says Inflation Has &#8216;Largely Been Wrung Out,&#8217; Pushes For Temporary Pause On China Tariffs To Shield US Businesses</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Walmart Analysts: Strategy Curbs Price Hikes Despite Tariffs

CTRI

Centuri Holdings shares are trading lower following Q1 financial results.

Apogee Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>) on Monday revealed interim data from its Phase 1b trial of APG808, a novel half-life extended IL-4Rα antibody, in patients with <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45342426/apogee-therapeutics-announces-positive-interim-results-from-the-phase-1b-trial-of-apg808-its-novel" rel="noreferrer noopener">mild-to-moderate asthma</a>.
The Phase 1b double-blind, placebo-controlled, multiple-dose trial evaluated the safety and tolerability of APG808 in 22 adult patients with mild-to-moderate asthma.
The trial also evaluated fractional exhaled nitric oxide concentration (FeNO), TARC, and pSTAT6.
Participants were randomized 3:1, receiving 600mg of APG808 or placebo on day 1 and day 29.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44084945/apogee-therapeutics-investigational-atopic-dermatitis-potential-shows-strong-tolerability-extended-half-life-in-early-trial" rel="noreferrer noopener">Apogee Therapeutics&#8217; Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial</a>
The study showed that a multiple-dose regimen of APG808 was well tolerated in asthmatic patients through 12 weeks of available follow-up. The most common treatment-emergent adverse events (TEAEs) observed were headache, injection site erythema, and upper respiratory tract infections.
The company said there were no Grade 3 TEAEs or severe adverse events. No adverse events led to study discontinuation.
Also, multiple doses of APG808 resulted in rapid suppression of FeNO, a biomarker of Type 2 inflammation that is associated with asthma exacerbations. At 12 weeks, there was a maximal robust FeNO decrease from a baseline of 53% and a sustained FeNO decrease from a baseline of 50%.
APG808 also demonstrated a sustained and near-complete reduction in pSTAT6 and deep reduction of TARC, maintained through 12 weeks, two key Type 2 inflammatory biomarkers.
APG808&#8217;s optimized formulation, potential best-in-class PK profile, and durable FeNO suppression for 12 weeks support the potential for 2-month or longer maintenance dosing.
Apogee Therapeutics&#8217; reported cash, cash equivalents, and marketable securities were $681.4 million as of March 31, 2025.
Based on current operating plans, Apogee expects its existing cash, cash equivalents, and marketable securities will enable the company to fund its operating expenses into the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45342743/apogee-therapeutics-provides-business-update-pipeline-progress-and-reports-first-quarter-2025-fina" rel="noreferrer noopener">first quarter of 2028</a>.
Price Action: APGE stock is up 7.80% at $40.20 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45349416/blade-beats-q1-forecasts-as-jet-surge-short-flights-drive-gains" target="_blank" rel="noreferrer noopener">Blade Beats Q1 Forecasts As Jet Surge, Short Flights Drive Gains</a></li>
</ul>
Image via Shutterstock

Biotech

Earnings

Health Care

APGE

Why Is Apogee Therapeutics Stock Trading Higher On Monday?

In April, Medicus Pharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDCX#NASDAQ">MDCX</a>) agreed to acquire all of Antev&#8217;s issued and outstanding <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">shares on a share exchange</a>.
Antev is a clinical-stage biotech company developing Teverelix, a next-generation GnRH antagonist, as the first in-market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention (AURr) episodes due to an enlarged prostate.
Medicus <a target="_blank" href="https://medicuspharma.com/medicus-pharma-ltd-announces-a-binding-letter-of-intent-to-acquire-antev-ltd-for-us75-million-in-a-share-exchange-transaction/" rel="noreferrer noopener">will</a> negotiate and enter into a definitive agreement with Antev in exchange for 2.67 million (or approximately 19%) shares.
Antev shareholders will be entitled to receive up to approximately $65 million in additional contingent consideration tied to potential future FDA Phase 2 and New Drug Application approvals.
The transaction is expected to close before the end of June.
D. Boral Capital on Monday raised the price target from $14 to $27, <a target="_blank" href="https://www.benzinga.com/quote/MDCX/analyst-ratings" rel="noreferrer noopener">with a Buy rating</a>.
&#8220;With no approved drug for AUR recurrence and an estimated $2 billion addressable U.S. market, Teverelix has the potential to become a first-in-class therapy with a differentiated safety and dosing profile,&#8221; said analyst Jason Kolbert. &#8220;We view this transaction as a savvy, de-risked pipeline expansion that materially enhances Medicus&#8217; near-commercial portfolio and positions the company for accelerated value creation.&#8221;
He added that Medicus is expanding into men&#8217;s health and urology by acquiring a first-in-class drug with low trial costs and a focused sales strategy targeting urologists.
Since this new program doesn&#8217;t overlap with Medicus&#8217; existing ones, the deal fits well with its overall strategy. It could add value, especially if Teverelix moves smoothly into Phase 3 trials and hits the market before 2030.
In March, Medicus Pharma announced a positively trending interim analysis for the SKNJCT-003 Phase 2 clinical study to non-invasively treat basal cell carcinoma of the skin (BCC).
The interim analysis shows the clinical study SKNJCT-003 is trending positively, with a proportion of subjects with complete clinical clearance of more than 60%.
The analysis also shows that the investigational product, D-MNA, was well tolerated for both dose levels, a low-dose group receiving 100 ug of D-MNA and a high-dose group receiving 200 ug of D-MNA, in all participants so far enrolled in the study, with no dose-limiting toxicities (DLTs) or <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44162661/medicus-pharma-ltd-announces-positively-trending-interim-analysis-for-sknjct-003-phase-2-clinical-" rel="noreferrer noopener">serious adverse events (SAEs)</a>.
The company plans to submit the interim analysis to the United States Food and Drug Administration (FDA) as part of a package seeking a Type C meeting with the FDA in Q2 2025.
Price Action: MDCX stock is up 15.8% at $5.31 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/health-care/25/05/45353362/surgery-partners-misses-q1-marks-but-sticks-to-2025-outlook" target="_blank" rel="noreferrer noopener">Surgery Partners Misses Q1 Marks But Sticks To 2025 Outlook</a></li>
</ul>
Photo: Shutterstock

MDCX

Medicus Pharma's 'Savvy' Antev Deal De-Risks Pipeline Expansion, Enhances Near-Commercial Portfolio

DOLE

Dole shares are trading lower after the company reported worse-than-expected Q1 adjusted EPS results.

Loop Capital analyst Jeffrey Stevenson maintains Installed Building Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBP#NYSE">IBP</a>) with a Buy and lowers the price target from $210 to $200.

Loop Capital Maintains Buy on Installed Building Prods, Lowers Price Target to $200

IBEX

IBEX shares are trading lower after Baird downgraded the stock from Outperform to Neutral.

Susquehanna analyst Shyam Patil maintains Ziff Davis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZD#NASDAQ">ZD</a>) with a Positive and lowers the price target from $80 to $45.

Susquehanna Maintains Positive on Ziff Davis, Lowers Price Target to $45

SNDA

Sonida Senior Living shares are trading higher after the company reported Q1 financial results and beat its EPS and sales estimates.

Susquehanna analyst Aaron Samuels maintains Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) with a Neutral and lowers the price target from $170 to $140.

Susquehanna Maintains Neutral on Cloudflare, Lowers Price Target to $140

Loop Capital analyst Chris Dankert maintains WESCO Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WCC#NYSE">WCC</a>) with a Buy and lowers the price target from $250 to $220.

Loop Capital Maintains Buy on WESCO Intl, Lowers Price Target to $220

ARKO

ARKO shares are trading higher. BMO Capital raised its price target on the stock from $4 to $4.5.

KeyBanc Capital Markets analyst Steve Barger upgrades Federal Signal Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSS#NYSE">FSS</a>) to Overweight from Sector Weight <a href="https://www.benzinga.com/quote/fss/analyst-ratings" target="_blank" rel="noreferrer noopener">with a price forecast of $110</a>.
The analyst says that following recent investor meetings, he is impressed by FSS&#8217;s strategic focus on specific competitors and its continuous efforts to enhance its competitive strengths.
The analyst anticipates solid organic growth driven by market share gains, R&amp;D investments, pricing strategies and expanded original equipment (OE) and aftermarket offerings through its service center network, which facilitates customer acquisition.
Inorganically, Barger expects FSS to continue acquiring strong regional OEMs and leveraging its national footprint to distribute its products, thereby strengthening its portfolio of aspirational brands.
The analyst believes this combination, along with the culture of continuous improvement, could lead to robust revenue growth, improved profit margins and strong cash generation.
Going forward, successful execution of these strategies should make Federal Signal increasingly difficult for smaller competitors to challenge, adds the analyst.
The analyst&#8217;s positive outlook assumes the company can successfully increase truck production, as achieving its guidance necessitates record revenue quarters moving forward.
For 2025, the analyst raises its EPS estimates to $3.84 (from $3.80) versus consensus of $3.81 based on 12% revenue growth at an incremental margin of 24%.
For 2026, Barger boosts EPS estimates to $4.31 from $4.25 (versus cons $4.29), with revenue growth of 7% and 26% incremental margin.
FSS Price Action: Federal Signal Corp shares are up 4.41% at $93.51&nbsp;at publication on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com//node/45079085" target="_blank" rel="noreferrer noopener">PACCAR Misses&nbsp;Q1&nbsp;Earnings, Blames Tariff Turmoil For Hitting North American Truck Market</a></li>
</ul>
Photo: MacroEcon via Shutterstock

Mid Cap

Federal Signal Gets A Green Light: Analyst Sees Widening Moat Against Competitors And More

Susquehanna analyst Shyam Patil maintains Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) with a Neutral and raises the price target from $15 to $18.

LYFT

Susquehanna Maintains Neutral on Lyft, Raises Price Target to $18

Loop Capital analyst Alton Stump maintains FAT Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAT#NASDAQ">FAT</a>) with a Buy and lowers the price target from $12 to $10.

Loop Capital Maintains Buy on FAT Brands, Lowers Price Target to $10

Press Releases

Bruker Appoints Laura Francis to its Board of Directors

Progyny, Inc. Announces Fourth Quarter 2024 Results

Progyny, Inc. to Participate in Upcoming Investor Conferences

Progyny Expands Family Building Solutions with New Parent and Child Well-being Offering

Progyny Expands Maternal Health Support with Addition of Doula Services

Financing

The Broken Brown Egg and Progyny Announce the 2025 Awareness, Hope, and Activism Grant™ to Support BIPOC Individuals and Couples in Family Building

Progyny to Host Events Honoring Individuals, Families and Infertility Throughout National Infertility Awareness Week® and Canadian Fertility Awareness Week®

Comments

Progyny

Noticias

Últimas noticias sobre Progyny (NASDAQ:PGNY) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL